EQS-Adhoc: Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital in-crease of up to 154,053 shares

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital
   Increase
   Marinomed Biotech AG: Publication of a report on the exclusion of
   subscription rights for a possible second cash capital in-crease of up to
   154,053 shares

   27-Nov-2024 / 12:49 CET/CEST
   Disclosure of an inside information acc. to Article 17 MAR of the
   Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
   Group AG.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Korneuburg, Austria, 27. November 2024 -  As Marinomed Biotech AG (the
   "Company" or "Marinomed") announced in its ad hoc announcement dated 18
   September 2024 regarding the first cash capital increase of 154,053 new
   shares (the "First Cash Capital Increase"), the Company is negotiating
   with investors regarding a possible second cash capital increase, which
   would be carried out in accordance with the authorisation to exclude the
   subscription rights of existing shareholders (the "Second Capital
   Increase"). Marinomed is currently continuing to discuss with several
   investors such a Second Capital Increase, although no agreements or board
   resolutions have yet been reached.

   The Company's Management Board has resolved today to publish a report on
   the intended exclusion of subscription rights of existing shareholders for
   a possible cash capital increase of up to EUR 154,053 by issuing up to
   154,053 new no-par value bearer shares against cash contribution (the
   "Report"). The Report on the exclusion of subscription rights is to be
   published as soon as possible on the electronic announcement and
   information platform of the Federal Government of Austria ("EVI").

   With the publication of the Report, the Company's Management Board ensures
   that, in the event of a short-term financing requirement of the Company,
   the Company's Management Board is legally in a position to resolve on a
   new cash capital increase from the authorised capital 2024 in accordance
   with § 5 para (6) of the Company's Articles of Association (the
   "Authorised Capital 2024") at short notice with the approval of the
   Supervisory Board. The background to this is that a report on the planned
   exclusion of subscription rights must be published at least two weeks
   prior to the required Supervisory Board resolution. Against the background
   of the cash ratio to be deposited in accordance with the adopted
   restructuring plan, the Company is creating the prerequisite for being
   able to raise necessary equity at short notice and not having to wait for
   the two-week period to expire in this case.

   The actual implementation of a possible Second Capital Increase remains
   dependent on the outcome of negotiations with investors, the conclusion of
   the respective transaction documents and the adoption of resolutions by
   the Company's Management Board and Supervisory Board. In addition, the
   restructuring proceedings (still needed for a Second Capital Increase)
   require the approval by the restructuring administrator.

   +++ End of ad-hoc announcement +++

    

   End of Inside Information

   ══════════════════════════════════════════════════════════════════════════

   27-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 2039559


    
   End of Announcement EQS News Service


   2039559  27-Nov-2024 CET/CEST

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT |

print